Skip to main content
. 2021 Jun 23;13(13):3134. doi: 10.3390/cancers13133134

Figure 1.

Figure 1

Gross cost of first-line CLL treatment (drugs only), Czech Republic, 2021. The price is in thousands of EUR and reflects median duration of therapy in the published studies. Venetoclax is currently not reimbursed for the first-line CLL therapy in the Czech Republic. G-CLB, obinutuzumab + chlorambucil; BR, bendamustine + rituximab; FCR, fludarabine + cyclophosphamide + rituximab; VG, venetoclax + obinutuzumab.